Compatibility «Efavirenz» and «Dexamethasone»
Between «Efavirenz» and «Dexamethasone» found 2 dangerous and 16 negative interactions, joint admission is not recommended without consulting a doctor.
Interaction tableCompare |
Dexamethasone |
✘Efavirenz Analogs | |
✘Dexamethasone Analogs |
-
Interactions Efavirenz with Dexamethasone
-
Dangerous interactions
Efavirenz is contraindicated to be taken simultaneously with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil and ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine or methylergonovine), since the competitive interaction of efavirenz with the CYP3A4 isoenzyme can lead to suppression of the metabolism of these drugs and the appearance of prerequisites for the occurrence of serious and/ or life-threatening adverse events (for example, cardiac arrhythmia, prolonged sedation, or respiratory depression). Concomitant administration with grazoprevir / elbasvir is contraindicated because it can lead to a loss of virological activity of grazoprevir / elbasvir due to a significant decrease in plasma concentrations of grazoprevir and elbasvir, due to the induction of the CYP3A4 or P‑gp isoenzyme by efavirenz. -
Negative interactions
With simultaneous use of efavirenz, which is an inducer of CYP3A4 in vivo, plasma concentrations of other compounds that are substrates of CYP3A4 may decrease. Drugs that induce CYP3A4 activity (for example, phenobarbital, rifamycin, rifabutin, etc.) can increase the clearance of efavirenz, which leads to a decrease in plasma concentration. Theoretically, this can lead to increased exposure to CYP3A4 substrates, therefore caution should be exercised when using CYP3A4 substrates with a narrow therapeutic window. Efavirenz exposure may increase when the drug is used simultaneously with certain medications (for example, ritonavir) or food products (for example, grapefruit juice) that inhibit CYP3A4 or CYP2B6 isoenzymes. A similar decrease in indinavir exposure was observed in cases when indinavir (1000 mg k8h) was administered in combination with efavirenz (600 mg 1 time per day) (induction of CYP3A4). When tenofovir disoproxil/emtricitabine/efavirenz was co-administered with velpatasvir/sofosbuvir or with velpatasvir/voxilaprevir/sofosbuvir, a significant decrease in plasma concentrations of velpatasvir was shown due to induction of the CYP3A4 isoenzyme by efavirenz, which may lead to loss of the therapeutic effect of velpatasvir. (decrease in concentrations due to induction of CYP3A4). (decrease in carbamazepine concentrations due to induction of the CYP3A4 isoenzyme. Decrease in efavirenz concentrations due to induction of the isoenzyme CYP3A4 and CYP2B6). calcium channels, which are substrates of the CYP3A4 isoenzyme, may reduce the concentration of this blocker in blood plasma. A decrease in the exposure of etonogestrel (induction of CYP3A4) can be expected. Immunosuppressants that are metabolized by the CYP3A4 isoenzyme (e.g. cyclosporine, tacrolimus, sirolimus)/Efavirenz. A decrease in immunosuppressant exposure (induction of CYP3A4) can be expected. Concomitant use may lead to a decrease in antiretroviral efficacy and the potential development of viral resistance to atazanavir, the possibility of using an alternative GCS should be considered. Concomitant use of darunavir with dexamethasone should be avoided, which may lead to a decrease in antiretroviral efficacy and the potential development of viral resistance to darunavir, and the possibility of using an alternative GCS should be considered. With simultaneous use, the patient's condition should be monitored for changes in clinical efficacy and the need to adjust antiretroviral therapy. -
Unclear interactions
In vivo, it is an inducer of the isoenzymes CYP3A4, CYP2B6 and UDP‑GT1A1. At the same time, in vitro efavirenz inhibited the CYP3A4 isoenzyme. (induction of CYP3A4). (inhibition of CYP3A4). (induction of the CYP3A4 isoenzyme). (induction of CYP3A4 and CYP2B6).
-
Dangerous interactions
Decoding the colors of interactions and contraindications
Dangerous | — | a pronounced negative interaction or contraindication. |
Negative | — | negative interaction or side effect that may reduce effectiveness. |
Positive | — | the interaction can SOMETIMES be used as a positive (often a dose adjustment is needed), or it is an indication of the drug. |
No | — | the drugs do NOT interact, which is separately indicated in the instructions. |
Unclear | — | the system failed to pre-assess the danger. |
Video instruction
Additional information
- Kiberis checks interactions and evaluates drug compatibility online right in the instructions thanks to the latest artificial intelligence technologies. The accuracy of finding is more than 95%, the accuracy of the hazard assessment is more than 80%. The online medical service takes into account all the drug groups of the selected drugs and all their components. And since the database contains 25,000 drugs with detailed instructions, not every pharmacologist can compete with our artificial intelligence. List of popular interactions.
- Why do I need to
- Avoid dangerous prescriptions for your patients.
- Check the contraindications.
- Evaluate the safety of therapy in the treatment of children.
- See the compatibility of drugs with alcohol (enter it as a drug).
- Point the doctor to the found interaction - you may need to adjust the therapy.
- The use of information about interactions is only possible as an introduction. This information should not be used to adjust therapy without consulting a specialist.
- The article is written: artificial intelligence Kiberis
- Sources: official instructions for medicines and their active substances, as well as inter-group interactions described in medical studies and textbooks.
- Total analyzed: 169,974,420 possible combinations of drugs and their components were found 412,510 interacting combinations.
- Medicine section: Standard evidence-based medicine
- The date of the last update of the interaction database: 2024-05-02
Category - medicine